Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.

Molecular cancer - 19 Jun 2014

Arozarena Imanol, Goicoechea Ibai, Erice Oihane, Ferguson Jennnifer, Margison Geoffrey P, Wellbrock Claudia

Abstract excerpt

BACKGROUND: The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent. In melanoma, the existence of a BRAF mutation is a main predictor for successful BRAF-targeted therapy. However, despite initial successes with these therapies, patients relapse within a year and have to move on to other therapies. Moreover, patients harbouring a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Temozolomide
Share to Dacarbazine
Share to DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to GTP Phosphohydrolases

Share to Melanoma

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 24941944
DOI: 10.1186/1476-4598-13-154
PMCID: PMC4079649

Genes

BRAF
NRAS
DHFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.PMID 24941944Read ↗

Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?Semantic proximity Read ↗

MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS -, and NF1 -Mutant MelanomasSemantic proximity Read ↗

Expression of DNA repair proteins hMSH2, hMSH6, hMLH1,O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistanceSemantic proximity Read ↗

Genomic and Molecular Profiling Predicts Response to Temozolomide in MelanomaSemantic proximity Read ↗

Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma.Semantic proximity Read ↗

In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation.Semantic proximity Read ↗

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.Semantic proximity Read ↗

Tumors carrying BRAF-mutations over-express NAMPT that is genetically amplified and possesses oncogenic properties.Semantic proximity Read ↗

MGMT Expression Predicts PARP-Mediated Resistance to TemozolomideSemantic proximity Read ↗

Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.Semantic proximity Read ↗

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcomeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.